Literature DB >> 12932824

Lithium reduced N-methyl-D-aspartate receptor subunit 2A tyrosine phosphorylation and its interactions with Src and Fyn mediated by PSD-95 in rat hippocampus following cerebral ischemia.

Juan Ma1, Guang-Yi Zhang.   

Abstract

Recently, the neuroprotective effects of lithium against excitotoxicity mediated by N-methyl-D-aspartate (NMDA) receptors have been demonstrated. Since brain ischemia results in NMDA receptor over-excitation and Src family protein tyrosine kinase-mediated tyrosine phosphorylation of NMDA receptor subunit 2A (NR2A) enhances NMDA receptor activity, we examined the effects of lithium on tyrosine phosphorylation of NR2A and its interactions with Src and Fyn (two members of the Src family of protein tyrosine kinases) mediated by PSD-95 (postsynaptic density protein 95 kDa) after 6 h of reperfusion following 15 min of ischemia (I/R), which was induced by occlusion of the four vessels in Sprague-Dawley rats. After abdominal injection of LiCl (2 mg/kg) for 7 days, the data showed that together with the significant decrease in I/R-induced tyrosine phosphorylation of NR2A, the interactions of NR2A with Src and Fyn mediated by PSD-95 were also decreased significantly. However, lithium pretreatment did not alter the total protein levels of NR2A, Src, Fyn and PSD-95. These results suggest that the inhibition of NR2A tyrosine phosphorylation and its interactions with Src and Fyn mediated by PSD-95 may contribute to the lithium-induced downregulation of NMDA receptor function and provide neuroprotection against excitotoxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12932824     DOI: 10.1016/s0304-3940(03)00784-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  22 in total

1.  In vivo therapeutic gas delivery for neuroprotection with echogenic liposomes.

Authors:  George L Britton; Hyunggun Kim; Patrick H Kee; Jaroslaw Aronowski; Christy K Holland; David D McPherson; Shao-Ling Huang
Journal:  Circulation       Date:  2010-10-04       Impact factor: 29.690

Review 2.  Fyn in Neurodevelopment and Ischemic Brain Injury.

Authors:  Renatta Knox; Xiangning Jiang
Journal:  Dev Neurosci       Date:  2015-02-17       Impact factor: 2.984

Review 3.  A new neurological focus in neonatal intensive care.

Authors:  Sonia L Bonifacio; Hannah C Glass; Susan Peloquin; Donna M Ferriero
Journal:  Nat Rev Neurol       Date:  2011-08-02       Impact factor: 42.937

Review 4.  Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models.

Authors:  Zhi-fei Wang; Emily Bame Fessler; De-Maw Chuang
Journal:  Acta Pharmacol Sin       Date:  2011-11-07       Impact factor: 6.150

Review 5.  Neuroprotective action of lithium in disorders of the central nervous system.

Authors:  Chi-Tso Chiu; De-Maw Chuang
Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban       Date:  2011-06

Review 6.  The Role of GluN2A in Cerebral Ischemia: Promoting Neuron Death and Survival in the Early Stage and Thereafter.

Authors:  Yongjun Sun; Xiaokun Cheng; Jie Hu; Zibin Gao
Journal:  Mol Neurobiol       Date:  2017-01-19       Impact factor: 5.590

Review 7.  The neurotrophic and neuroprotective effects of psychotropic agents.

Authors:  Joshua Hunsberger; Daniel R Austin; Ioline D Henter; Guang Chen
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

Review 8.  Neuroprotection in the newborn infant.

Authors:  Fernando F Gonzalez; Donna M Ferriero
Journal:  Clin Perinatol       Date:  2009-12       Impact factor: 3.430

Review 9.  The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis.

Authors:  Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Bipolar Disord       Date:  2009-06       Impact factor: 6.744

Review 10.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.